Citius Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Citius Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $22 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-26.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 61% of Healthcare companies in United States.
Cash Cushion Ratio
+24%Cash, after subtracting all debt, equals 24% of its market value (net cash).
Higher than 65% of Healthcare companies in United States.
Tangible Assets Ratio
22%Of every $100 the company owns, $22 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 96% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 88% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Citius Pharmaceuticals, Inc. made a loss over the last year. Citius Pharmaceuticals, Inc. owes $0.47 for every $1 it owns. Citius Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossCitius Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.15The share price is 0.15 times Citius Pharmaceuticals, Inc.'s book value per share, lower than almost all Healthcare companies in United States.
Market cap
$10 MThe total market value of all of Citius Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$67 MWhat Citius Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.43Net worth divided by the number of shares. The share price of $0.37 is 0.2 times this, which is the P/B above.
Return on equity (ROE)
-81.1%Citius Pharmaceuticals, Inc. lost 81.1% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.47×Citius Pharmaceuticals, Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NoneCitius Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossCitius Pharmaceuticals, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCitius Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Sep 2025.
Cash vs debt
Net cashCitius Pharmaceuticals, Inc. held $2 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Citius Pharmaceuticals, Inc.: $10 M ÷ $67 M (30 Jun 2026) = 0.2.
What is Citius Pharmaceuticals, Inc.'s return on equity?
Citius Pharmaceuticals, Inc. lost 81.1% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does Citius Pharmaceuticals, Inc. owe compared with what it owns?
Citius Pharmaceuticals, Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does Citius Pharmaceuticals, Inc. pay a dividend?
No. Citius Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.